Data Foundry

Drug recalls 2022

Aspirin and Extended-Release Dipyridamole Capsules — Class III drug recall D-1282-2022

Ongoing recall by Glenmark Pharmaceuticals Inc., USA, reported 2022-07-27, distributed nationwide. Failed Tablet/Capsule Specification : Capsule breakage

Recall numberD-1282-2022
Product typeDrug
ClassificationClass III
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmGlenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States
Recall initiated2022-06-29
Classified2022-07-18
Reported by FDA2022-07-27
DistributedNationwide (US)
Quantity168,936 bottles
Reason classesdevice malfunction
NDC68462-0405, 68462-0405-30, 68462-0405-60
Lot numbers17201639, 17201759, 17202067, 17210092, 17210145, 17210696, 17210732, 17211062, 17211441, 17211670, 17211810, 17211862, 17212020, 17212068, 17212438, 17220172, 17220251
Expiration dates2022-08, 2022-09, 2022-10, 2022-11, 2022-12, 2023-02, 2023-04, 2023-05, 2023-06, 2023-07, 2023-08, 2023-10, 2023-12

Product

Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-405-60.

Reason for recall

Failed Tablet/Capsule Specification : Capsule breakage

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1282-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.